Promethazine adverse events after implementation of a medication shortage interchange

Annals of Pharmacotherapy

Volumn 39, Issue 2, 2005, Pages 255-261

  Sheth, Heena S ^a,c   Verrico, Margaret M ^a,b   Skledar, Susan J ^a,b   Towers, Adele L ^c,d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c University of Pittsburgh ^*  (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse drug reaction reporting systems; Hospital formularies; Promethazine; Therapeutic interchange

Indexed keywords

ANTIEMETIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; DEXTROPROPOXYPHENE; DIPHENHYDRAMINE; HYDROMORPHONE; LORAZEPAM; METOCLOPRAMIDE; MORPHINE; NALOXONE; OPIATE; OXYBUTYNIN; OXYCODONE; PROCHLORPERAZINE; PROMETHAZINE; SCOPOLAMINE; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DOSE RESPONSE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG USE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GERIATRICS; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; MALE; NAUSEA; OCULOGYRIC CRISIS; PERITONITIS; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RISK FACTOR; SEDATION; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROMETHAZINE;

EID: 12844251276     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E361     Document Type: Article

References (27)

1. American Society of Health-System Pharmacists. Drug Shortages Resource Center.www.ashp.org/shortage/antiemetic.cfm (accessed 2004 Mar 14).
2. United States Food and Drug Administration. FDA Medwatch: www. fdagov/medwatch/safety/2001/inapsine.htm (accessed 2004 Mar 2).
3. Bailey P, White PF. Droperidol editorial: making a mountain out of a molehill! (letter). Anesthesiology 2003;99:760-1; author reply 761.
4. Chang N, Simone A, Schultheis L, Rappaport B. Reviewing case reports and the droperidol warning: FDA response (letter). Anesth Analg 2003;97:1542.
5. Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Droperidol, QT prolongation, and sudden death: what is the evidence? Ann Emerg Med 2003;41: 546-58. DOI 10.1067/mem.2003.110
6. Gan TJ, White PF, Scuderi PE, Watcha MF, Kovac A. FDA "black box" warning regarding use of droperidol for postoperative nausea and vomiting: is it justified? (letter). Anesthesiology 2002;97:287.
7. Horowitz BZ, Bizovi K, Moreno R. Droperidol - behind the black box warning (letter). Acad Emerg Med 2002;9:615-8.
8. Prescribing information. Phenergan (promethazine HCl) injection. Deerfield, IL: Baxter Healthcare, June 2004.
9. Skledar SJ, Hess MM. Implementation of a drug use and disease management program. Am J Health Syst Pharm 2000;57(suppl 4):S23-9.
10. United States Food and Drug Administration. FDA drug shortages. www.fda.gov/cder/drug/shortages/default.htm (accessed 2004 Apr 30).
11. American Society of Health-System Pharmacists. Drug Shortages Resource Center. www.ashp.org/shortage/index.cfm (accessed 2004 Apr 30).
12. Nahata MC, Clotz MA, Krogg EA. Adverse events of meperidine, promethazine and chlorpromazine for sedation in pediatric patients. Clin Pediatr 1985;24:58-60.
13. Terndrup TE, Cantor RM, Madden CM. Intramuscular meperidine, promethazine and chlorpromazine: analysis of use and complications in 487 pediatric emergency department patients. Ann Emerg Med 1989;18:528-33.
14. Irvin SM. Identification of potential problems for elderly outpatients after preoperative medication: a case study. J Post Anesth Nurs 1995;10:159-62.
15. Verrico MM, Weber RJ, McKaveney TP, Ansani NT, Towers AL. Adverse drug events involving COX-2 inhibitors. Ann Pharmacother 2003;37:1203-13. DOI 10.1345/aph.1A212
16. Jones JK. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Commun Health 1982;5:58-67.
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
18. Ernst AA, Weiss SJ, Park S, Takakuwa KM, Diercks D. Prochlorperazine versus promethazine for uncomplicated nausea and vomiting in the emergency department: a randomized, double blind clinical trial. Ann Emerg Med 2000;36:89-94. DOI 10.1067/mem.2000.108652
19. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. New York: McGraw-Hill, 2002.
20. Adam K, Oswald I. The hypnotic effects of an antihistaminic: promethazine. Br J Clin Pharmacol 1986;22:715-7.
21. Pichlmayr I, Lips U. EEG - effects of promethazine. Study on 17 patients. Anesthetist 1980;29:18-25.
22. Cole MG, Pruneau FJ. Prognosis of delirium in elderly hospitalized patients. CMAJ 1993;149:41-6.
23. Murray AM, Levkoff SE, Wetle TT, Beckett L, Cleary PD, Schor JD, et al. Acute delirium and functional decline in the hospitalized elderly patient. J Gerontol 1993;48:M181-6.
24. Inouye SK, Viscoli CM, Horwitz RI, Hurst LD, Tinetti ME. A predictive model for delirium in hospitalized elderly medical patients based on admission characteristics. Ann Intern Med 1993;119:474-81.
25. Blankenship CR. Adverse reactions related to phenergan. Gastroenterol Nursing 2001;24:149-50.
26. Keeri-Szanto M. The mode of action of promethazine in potentiating narcotic drugs. Br J Anaesth 1974;46:918-24.
27. Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004;5:2-19.